Fig. 7
From: Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment
SAHA modulates cell cycle and apoptosis regulatory proteins in human breast cancer cells. MCF7, MDA-MB-231, and MDA-MB-435 cells were treated with dimethylsulfoxide (DMSO) alone (Con), or suberoylanilide hydroxamic acid (SAHA) at 4 µM for 24 hr or 48 hr, and then analyzed for protein expression of p53, p27, p21, Bcl-2, and Bax (A), as well as retinoblastoma protein (pRb). (B) by Western blots analysis. Cells in the right panel of Fig. B were treated for 48 hr; whereas, cells from all other panels were treated for 24 hr. The same blots were probed with actin as loading controls. Actin*: loading control for p53 and p27; Actin**: loading control for p21, Bcl-2, and Bax; Actin: loading control for pRb.